Atossa Therapeutics (ATOS) Q3 2026 earnings summary

Executive summary

• Clinical-stage pipeline centers on oral (Z)-endoxifen across breast cancer and rare-disease indications; no marketed products or current revenue.

• Q3 expenses and net loss declined YoY, but 9M operating cash use rose to $24.7M and cash fell to $20.6M; additional funding is needed to continue planned operations.

Financial highlights

• Q3 2026 operating expenses and operating loss were each $5.9M, versus $9.3M YoY; net loss was $5.6M versus $8.7M.

• Q3 basic and diluted loss per share was $0.56 versus $1.01; 9M loss per share was $2.58 versus $2.76.

• 9M operating expenses were $24.5M versus $25.7M; net loss was $23.7M versus $23.8M.

• 9M R&D expense fell 13% to $13.1M, primarily from lower trial and regulatory consulting costs; G&A rose 7% to $11.4M, reflecting litigation and other legal costs, partly offset by lower compensation.

• 9M interest income was $0.7M versus $1.9M, primarily reflecting lower average invested cash balances; no income tax provision was recorded.

Outlook and guidance

• Existing resources are expected to be insufficient for planned operations over the next 12 months; additional capital is needed, with no assurance financing will be available on acceptable terms.

• EVANGELINE top-line data are expected in Q2 2027 after participants complete the 28-week treatment protocol; enrollment was completed in Q2 2026.

• FDA IND clearance for (Z)-endoxifen in DMD and McCune-Albright syndrome is anticipated by early 2027, with Phase 2 trial starts expected in 2027.

• Final 24-month Karisma durability data were received in Q3 2026; Karisma follow-up results and selected I-SPY 2 data are scheduled for presentation at SABCS in December 2026.